Ergoteles’s Theravance Biopharma TBPH Stock Holding History

Ergoteles’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,500	Closed	-$296K	–	1683
2021 Q1	$296K	Buy	+14,500	New	+$276K	0.01%	566

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ergoteles's TBPH Position: Q2 2021 in Review

Ergoteles sold out of Theravance Biopharma (TBPH) in Q2 2021, closing a stake of 14,500 shares — an estimated $296K sold.

Ergoteles first reported a position in TBPH in Q1 2021 and held it in 1 quarter. The position peaked at $296K in Q1 2021. 108 funds tracked by Wall St. Rank hold TBPH as of Q2 2021.

Ergoteles reported no remaining Theravance Biopharma position as of Q2 2021 after selling out during the quarter.
Ergoteles sold 14,500 Theravance Biopharma shares in Q2 2021, an estimated $296K.
Ergoteles first reported a position in Theravance Biopharma in Q1 2021 and held it in 1 quarter.
Ergoteles's Theravance Biopharma position peaked at $296K in Q1 2021.
108 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2021.

Based on Ergoteles's 13F filing for Q2 2021, filed 12 Aug 2021.